deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT04216329

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

A Phase I Clinical Trial of Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Sponsor: National Cancer Institute (NCI)

Conditions Glioblastoma Gliosarcoma Newly Diagnosed
Interventions Anti-diarrheal Generic Radiation therapy (RT) Olanzapine Salt tablets Selective serotonin receptor (5-HT3) antagonists Selinexor Temozolomide
Updated 42 times since 2020 Last updated: Jan 13, 2026 Started: Jul 7, 2020 Primary completion: Sep 29, 2023 Completion: Jul 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Glioblastoma and Gliosarcoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 42 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Dec 2020 · 3 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jun 2025 · 7 months · monthly snapshot~Jun 2025 – ~Feb 2026 · 8 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

42 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Jun 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Nov 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 37 earlier versions

  1. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE1

  3. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE1

  4. Feb 2024 — Apr 2024 [monthly]

    Recruiting PHASE1

  5. Dec 2023 — Feb 2024 [monthly]

    Recruiting PHASE1

  6. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  7. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1

  8. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

  9. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  10. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1

  11. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1

  12. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

  13. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE1

  14. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE1

  15. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE1

  16. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  17. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  18. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  19. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  20. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  21. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE1

  22. Jan 2022 — Apr 2022 [monthly]

    Recruiting PHASE1

  23. Nov 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  24. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE1

  25. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  26. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  27. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  28. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  29. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  30. Sep 2020 — Dec 2020 [monthly]

    Recruiting PHASE1

  31. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  32. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  33. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE1

  34. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE1

  35. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE1

  36. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  37. Feb 2020 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations